AbbVie (ABBV) Cash from Financing Activities (2012 - 2026)

AbbVie (ABBV) has 15 years of Cash from Financing Activities data on file, last reported at $919.0 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $919.0 million, up 173.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.5 billion (up 38.99% YoY), and the FY2025 annual result was -$12.7 billion, down 144.18% from the prior year.
• Cash from Financing Activities improved to $919.0 million in Q1 2026 per ABBV's latest filing, from -$4.2 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $10.8 billion in Q1 2024 and troughed at -$9.6 billion in Q4 2022.
• A 5-year average of -$3.5 billion and a median of -$4.2 billion in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 119.66% in 2022, then jumped 274.73% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$9.6 billion in 2022, then soared by 53.82% to -$4.4 billion in 2023, then tumbled by 54.21% to -$6.9 billion in 2024, then soared by 39.28% to -$4.2 billion in 2025, then jumped by 122.06% to $919.0 million in 2026.
• Business Quant data shows ABBV's Cash from Financing Activities at $919.0 million in Q1 2026, -$4.2 billion in Q4 2025, and -$4.6 billion in Q3 2025.